S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President ...

The proceeds will allow the company to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 to treat intracerebral hemorrhage (ICH), an orphan disease with no currently approved ...

Welcome to today's Bioceres Crop Solutions Fiscal Second Quarter 2025 Financial and Operational Results. My name is Santja, and I will be your moderator for today's call. All lines will be muted ...

Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional patients ...

Bioceres Crop Solutions Corp (NASDAQ:BIOX) is set to release its Q2 2025 earnings on Feb 12, 2025. The consensus estimate for Q2 2025 revenue is $129.50 million, and the earnings are expected to ...

Lake Street analyst Ben Klieve maintained a Buy rating on Bioceres Crop Solutions (BIOX – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $5.55.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...